{"id":748445,"date":"2023-04-18T07:06:04","date_gmt":"2023-04-18T11:06:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\/"},"modified":"2023-04-18T07:06:04","modified_gmt":"2023-04-18T11:06:04","slug":"tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\/","title":{"rendered":"Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:left\">\n          <strong>CD3 antibody has emerged as an established and attractive target for Type 1 diabetes after the $2.9 billion acquisition of Provention Bio by Sanofi<\/strong>\n        <\/li>\n<li style=\"text-align:left\">\n          <strong>Mechanism of Action of Tiziana\u2019s first-in-class, only fully human CD3 antibody, intranasal foralumab, makes it an ideal candidate for Type 1 diabetes <\/strong>\n        <\/li>\n<li style=\"text-align:left\">\n          <strong>Tiziana initiates program to study both the treatment and the delay of type 1 diabetes using its convenient self-administered intranasal foralumab<\/strong><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"left\">NEW YORK, April  18, 2023  (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences Ltd.\u00a0(Nasdaq: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qIRkt0LLqf7sHsZOht6iJTICL-Zqud3JYYqZT7WY9tQyL-VMTC_HkEyUGe5-GfutDNxQ27XygOWsHLYj4vnEzz90OV-y10ujS4UeV1Xi_OnM6FVvsfHWwFBWA72rgbJh\" rel=\"nofollow noopener\" target=\"_blank\">TLSA<\/a>) (\u201cTiziana\u201d or the \u201cCompany\u201d), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that it is initiating a program to develop intranasal foralumab for the treatment or prevention of Type 1 Diabetes.<\/p>\n<p align=\"left\">\u201cWith the FDA approval of the humanized anti-CD3 mAb TZIELD\u2122 (teplizumab-mzwv injection) and then its subsequent announced acquisition of Provention Bio\u00a0by Sanofi for $2.9 billion<sup>1<\/sup>, CD3 has emerged as an established and attractive target for Type 1 Diabetes,\u201d commented Gabriele Cerrone, Executive Chairman, Founder and interim Chief Executive Officer of Tiziana. \u201cWe believed that having a fully human CD3 antibody may offer benefits to patients across many different chronic disease indications.\u201d<\/p>\n<p align=\"left\">\u201cThe potential of not requiring an injection or infusion and having a take-home self-administered nasally delivered therapy would offer additional benefit and convenience to sufferers of Type 1 Diabetes\u201d, stated Matthew W. Davis, M.D., RPh, Chief Medical Officer of Tiziana. \u201cAlthough given intranasal, our fully human anti-CD3 mAb foralumab has shown to release anti-inflammatory T regulatory cells throughout the body while returning pro-inflammatory effector T cells to their na\u00efve state.<sup>2<\/sup>\u00a0We are actively discussing various study designs with our Key Opinion Leaders as well as with an internationally known network of dedicated diabetes physicians. I believe that the data published in PNAS<sup>2<\/sup> shows that the novel immunomodulatory effects of our intranasal fully human anti-CD3 mAb foralumab may have an important role in the diabetes market.\u201d<\/p>\n<p align=\"left\">\n        <strong>About Foralumab<\/strong>\n      <\/p>\n<p align=\"left\">Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal foralumab Phase 2 trials are expected to start in the third quarter of 2023 in patients with non-active SPMS. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory human diseases.<sup>2<\/sup><\/p>\n<p align=\"left\">\n        <strong>About\u00a0Tiziana Life Sciences<\/strong>\n      <\/p>\n<p align=\"left\">Tiziana Life Sciences\u00a0is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana\u2019s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana\u2019s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana\u2019s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.<\/p>\n<p align=\"left\">For further inquiries:<\/p>\n<p align=\"left\">\n        <strong>Tiziana Life Sciences Ltd<\/strong>\n      <\/p>\n<p align=\"left\">Paul Spencer, Business Development and Investor Relations <br \/>+44 (0) 207 495 2379<br \/>email:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6htEiRfT3MgZgsdLsJhUtjuRymlIL8p8x9EY1XHkhUcscvgJ8Tk2b97-GImdQXJmyZXMrvm7-dnby3BEN8ZoZOPymygC5GNjbwEifkzata__5-7gTRoI5YIUN9t4FLZeYG5WgFszzLumnKnYPi-5cHDQ6p1ZY1Me6YxRFSwHrF7i2F36bCyLWo1mfyUWD4tmGPm2-6iCfD8ILic6mLDvwxqeAUtv1D7_vCLi_HbCESeDhGbeOM5iZy2s7Y54l0oRlNK6-p8Q3aTZY97y77diDRigJW5d_tBOpY-j66H_c-245MT-aJkPq7h2WayB9eQ-oD4wyvvtd4miXm4CbAoBphTlCWznvoA3L4cAyKatixUVpx3YdyuSlUabOND4mYWmi987vUFOL7DbrM5oI9Ai3B34tdlUDVD0-9MvLrjPzylB-WoxXWzICmy458xx_9msvifJ8-SBkRT4QngMD0kXl0GXDQ_KSID6onnljIxYaYq06RMucv9Ab8uYhnCVGJByQRRxiz0WEDImstvWe32J9Q==\" rel=\"nofollow noopener\" target=\"_blank\"><u>info@tizianalifesciences.com<\/u><\/a><\/p>\n<p align=\"left\">\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Irina Koffler<br \/>LifeSci Advisors, LLC<br \/>+1 646 970 4681<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d77stSFb2liPMAPlo74PVmd0u_6ut6Xn7v7V-sIi1STDUyJF834QxMPgSK_Nh-1haDss8BlUSdlrCD5Hcc1hk99OxUec0V3vHpQW187v0L3r828gT102oRQ_Y9y26fJm\" rel=\"nofollow noopener\" target=\"_blank\">ikoffler@lifesciadvisors.com<\/a><\/u><\/p>\n<p align=\"left\">\n        <u>____________________<br \/><\/u><br \/>\n        <sup>1<\/sup><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fLN9UWH9nmn_hRrwX9JcfEbYadxiarLHB0p5msExIeToxsPqSk5vzngoFM5SfS9gqESaNgwfTJguwtlDQ3AFKoWiqafk544OHmAJs6hz_pnyVZvJhZIyHGghKbzfSOfz5cn6ugGCmaSug27GE9weYxRVxdl9dE-hr8v-C45P2ajbA9Ogx1pdRVVEnreVo3nGtjGxyVU7dqY9kQFaXmvYq7C_553NRsTySrA7Qo-yyerL61DeDfo-ZGYsIzdsE5K_\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2023\/2023-03-13-06-00-00-2625367<\/a><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oPuQdMSKR4rZw6-0Jb7a3gHnEsrX5v_liYtwTLYmqNLKYVimOwv-rBBWE0afvIqWO7IjpVjarp83MaY9BUBTrfZ4kZUrJedG4rZFjXqD11l7jp3oEDbqOi5EVBpLlcObt8KmW4qumIcR68H4FiUygQ==\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <br \/>\n        <\/a><br \/>\n        <sup>2<\/sup><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fLN9UWH9nmn_hRrwX9JcfBejWUAmSTzd9nJ04PRo_CibhqEIW9IVuHfyA1pomgrJlSGmzEjFG_KbSLTfciKxymQeBdcPrkF66xsFvc64iP7Qyh6B70MbeyV3n0LNY6EwKkNHSNxM4k6v8GaeLJ6tmiakAqc6LIJCTRsgES0PqAw=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.pnas.org\/doi\/10.1073\/pnas.2220272120<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwOTQzMCM1NTMwMDEwIzIxMjM4ODU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OWJlMGI0YzMtMGExMi00ODE3LTg2YzItNWQ3MzkyYjVjN2U2LTExMzU0NTY=\/tiny\/Tiziana-Life-Sciences-Plc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CD3 antibody has emerged as an established and attractive target for Type 1 diabetes after the $2.9 billion acquisition of Provention Bio by Sanofi Mechanism of Action of Tiziana\u2019s first-in-class, only fully human CD3 antibody, intranasal foralumab, makes it an ideal candidate for Type 1 diabetes Tiziana initiates program to study both the treatment and the delay of type 1 diabetes using its convenient self-administered intranasal foralumab NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences Ltd.\u00a0(Nasdaq: TLSA) (\u201cTiziana\u201d or the \u201cCompany\u201d), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that it is initiating a program to develop intranasal foralumab for the treatment or prevention of Type 1 Diabetes. \u201cWith the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-748445","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CD3 antibody has emerged as an established and attractive target for Type 1 diabetes after the $2.9 billion acquisition of Provention Bio by Sanofi Mechanism of Action of Tiziana\u2019s first-in-class, only fully human CD3 antibody, intranasal foralumab, makes it an ideal candidate for Type 1 diabetes Tiziana initiates program to study both the treatment and the delay of type 1 diabetes using its convenient self-administered intranasal foralumab NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences Ltd.\u00a0(Nasdaq: TLSA) (\u201cTiziana\u201d or the \u201cCompany\u201d), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that it is initiating a program to develop intranasal foralumab for the treatment or prevention of Type 1 Diabetes. \u201cWith the &hellip; Continue reading &quot;Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-18T11:06:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwOTQzMCM1NTMwMDEwIzIxMjM4ODU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes\",\"datePublished\":\"2023-04-18T11:06:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\\\/\"},\"wordCount\":568,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwOTQzMCM1NTMwMDEwIzIxMjM4ODU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\\\/\",\"name\":\"Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwOTQzMCM1NTMwMDEwIzIxMjM4ODU=\",\"datePublished\":\"2023-04-18T11:06:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwOTQzMCM1NTMwMDEwIzIxMjM4ODU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwOTQzMCM1NTMwMDEwIzIxMjM4ODU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\/","og_locale":"en_US","og_type":"article","og_title":"Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes - Market Newsdesk","og_description":"CD3 antibody has emerged as an established and attractive target for Type 1 diabetes after the $2.9 billion acquisition of Provention Bio by Sanofi Mechanism of Action of Tiziana\u2019s first-in-class, only fully human CD3 antibody, intranasal foralumab, makes it an ideal candidate for Type 1 diabetes Tiziana initiates program to study both the treatment and the delay of type 1 diabetes using its convenient self-administered intranasal foralumab NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences Ltd.\u00a0(Nasdaq: TLSA) (\u201cTiziana\u201d or the \u201cCompany\u201d), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that it is initiating a program to develop intranasal foralumab for the treatment or prevention of Type 1 Diabetes. \u201cWith the &hellip; Continue reading \"Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-18T11:06:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwOTQzMCM1NTMwMDEwIzIxMjM4ODU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes","datePublished":"2023-04-18T11:06:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\/"},"wordCount":568,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwOTQzMCM1NTMwMDEwIzIxMjM4ODU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\/","name":"Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwOTQzMCM1NTMwMDEwIzIxMjM4ODU=","datePublished":"2023-04-18T11:06:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwOTQzMCM1NTMwMDEwIzIxMjM4ODU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwOTQzMCM1NTMwMDEwIzIxMjM4ODU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-initiates-program-to-develop-intranasal-foralumab-in-type-1-diabetes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/748445","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=748445"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/748445\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=748445"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=748445"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=748445"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}